REGULATORY B CELLS (TBREGS) AND THEIR USE
    6.
    发明申请
    REGULATORY B CELLS (TBREGS) AND THEIR USE 有权
    调节B细胞(TBREGS)及其使用

    公开(公告)号:US20120308563A1

    公开(公告)日:2012-12-06

    申请号:US13577226

    申请日:2011-02-04

    摘要: Regulatory B cells (tBreg) are disclosed herein. These regulatory B cells express CD25 (CD25+) a pan B cell marker such as B220 (B220+), and also express CD19 (CD19+). These regulatory B cells suppress resting and activated T cells in cell contact-dependent manner. Methods for generating these regulatory B cells are also disclosed herein, as are methods for using these regulatory B cells to produce regulatory T cells (Treg). In some embodiments, methods for treating an immune-mediated disorder, such as an autoimmune disease, transplant rejection, graft-versus-host disease or inflammation, are disclosed. These methods include increasing regulatory B cell number or activity and/or by administering autologous regulatory B cells. Methods for treating cancer are also disclosed herein. These methods include decreasing regulatory B cell activity and/or number.

    摘要翻译: 本文公开了调节性B细胞(tBreg)。 这些调节性B细胞表达CD25(CD25 +)泛B细胞标记如B220(B220 +),并表达CD19(CD19 +)。 这些调节性B细胞以细胞接触依赖的方式抑制休息和活化的T细胞。 本文还公开了产生这些调节性B细胞的方法,以及使用这些调节性B细胞产生调节性T细胞(Treg)的方法。 在一些实施方案中,公开了用于治疗免疫介导的病症(例如自身免疫疾病,移植排斥,移植物抗宿主病或炎症)的方法。 这些方法包括增加调节性B细胞数或活性和/或通过施用自体调节性B细胞。 本文还公开了治疗癌症的方法。 这些方法包括降低调节性B细胞活性和/或数量。